Not Signed In -
Valsartan |
Diovan |
Image:Valsartan.png Valsartan Systematic (IUPAC) name 3-methyl-2- [pentanoyl-[ [4-[2-(2H-tetrazol-5-yl) phenyl] phenyl] methyl]amino] -butanoic acid Identifiers CAS number 137862-53-4 ATC code C09CA03 PubChem 60846 DrugBank APRD00133 Chemical data Formula C24H29N5O3 Mol. weight 435.519 g/mol Pharmacokinetic data Bioavailability ? Protein binding 95% Metabolism ? Half life 6 hours Excretion ? Therapeutic considerations Pregnancy cat. ...
Wikipedia - [full article]
Valsartan News Headlines
- Exforge® Approved In Europe As Powerful New Blood Pressure Therapy Combining Two Leading Medications In A Single Pill
MedicalNewsToday - Mon, 22 Jan 2007 08:00 EST
- Exforge® Receives US Regulatory Approval As A New And Highly Effective Treatment Option For Patients With High Blood Pressure
MedicalNewsToday - Thu, 28 Dec 2006 08:00 EST
- Exforge(R) Receives US Regulatory Approval As A New And Highly Effective Treatment Option For Patients With High Blood Pressure
MedicalNewsToday - Sun, 24 Dec 2006 08:00 EST
- Exforge® Receives Positive European Union Regulatory Opinion Supporting Approval As Effective New Treatment For Patients With High Blood Pressure
MedicalNewsToday - Thu, 23 Nov 2006 08:00 EST
- Diovan(R) (valsartan) Trial To Lower C-Reactive Protein, An Important Marker Of Inflammation
MedicalNewsToday - Sun, 21 May 2006 06:00 EST
- FDA Approves Higher Dose Formulations Of Diovan HCT(R) (valsartan/hydrochlorothiazide) For Treatment Of High Blood Pressure
MedicalNewsToday - Tue, 02 May 2006 06:00 EST
- Health Canada Approves Diovan (valsartan) to reduce cardiovascular death after heart failure
MedicalNewsToday - Sun, 25 Sep 2005 11:00 EST
- FDA approves Diovan® (valsartan) to reduce cardiovascular death in heart attack survivors at high risk
MedicalNewsToday - Sun, 07 Aug 2005 09:00 EST
- EU approves Diovan to treat people with heart failure
MedicalNewsToday - Mon, 13 Jun 2005 06:00 EST
- Diovan® receives EU approval for the treatment of heart attack survivors
MedicalNewsToday - Mon, 09 May 2005 04:00 EST
email this page
print this page
bookmark this page
feedback on this page
